Science Explorer Back to mapMap
Discussion
Topic · Surgery

Cholangiocarcinoma and Gallbladder Cancer Studies

Cholangiocarcinoma and Gallbladder Cancer Studies is a research topic within Surgery. Science Explorer counts 39k research works in it since 1950. 10.1% of them reached the world's top 10% most cited for their field and year.

This cluster of papers focuses on the diagnosis, management, epidemiology, and therapeutic strategies for cholangiocarcinoma, including intrahepatic and hilar cholangiocarcinoma. It covers topics such as surgical management, molecular pathology, and prognostic factors. The papers also discuss the increasing incidence and mortality of biliary tract cancers, as well as emerging targeted therapies.

  • Cholangiocarcinoma
  • Biliary Tract Cancer
  • Intrahepatic Cholangiocarcinoma
  • Hilar Cholangiocarcinoma
  • Gallbladder Cancer
  • Epidemiology
  • Therapeutic Strategies
  • Molecular Pathology
  • Surgical Management
  • Prognostic Factors
Research works
39k
fractional, since 1950
In the world top 10%
3.9k
per year above
Top-10% rate
10.1%
share of its works in the world top 10%
Growth, 2018-21 → 2022-25
+7%
the tick is no change
Largest producer
China
35% of the 10 largest, 2022-now
Cholangiocarcinoma and Gallbladder Cancer Studies

This ranks research output and citation impact. It says nothing about the quality of diagnosis, treatment or care.

Which countries lead Cholangiocarcinoma and Gallbladder Cancer Studies research?

By volume, China and the United States publish the most (2.6k and 1.6k works in 2022-now).

By volume, 2022-now

  1. 1 China 2.6k works
  2. 2 United States 1.6k works
  3. 3 Japan 943 works
  4. 4 India 449 works
  5. 5 South Korea 444 works
  6. 6 Italy 363 works
  7. 7 Germany 291 works
  8. 8 United Kingdom 285 works
  9. 9 France 197 works
  10. 10 Spain 160 works

How concentrated that is

The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.

China: 35.4%United States: 21.8%Japan: 12.9%India: 6.1%6 others listed: 23.7%35%largest
China2,599 · 35.4%United States1,602 · 21.8%Japan943 · 12.9%India449 · 6.1%6 others listed1,741 · 23.7%

Shares of the rows listed above, not of the whole node.

Which institutions lead Cholangiocarcinoma and Gallbladder Cancer Studies research?

By volume in 2022-now, Sun Yat-sen University publishes the most Cholangiocarcinoma and Gallbladder Cancer Studies research, followed by Sichuan University and Mayo Clinic.

Who are the leading researchers in Cholangiocarcinoma and Gallbladder Cancer Studies?

The most-cited researchers publishing on Cholangiocarcinoma and Gallbladder Cancer Studies include Ahmedin Jemal, Freddie Bray and Eric S. Lander.

  1. 1 Ahmedin Jemal United States 761k citations
  2. 2 Freddie Bray France 550k citations
  3. 3 Eric S. Lander United States 524k citations
  4. 4 Zhong Lin Wang United States 491k citations
  5. 5 Jacques Ferlay France 486k citations
  6. 6 Ali H. Mokdad United States 429k citations
  7. 7 Walter Churchill Willett United States 411k citations
  8. 8 Stacey L. Gabriel United States 402k citations
  9. 9 Guido Kroemer France 386k citations
  10. 10 Bert Vogelstein United States 373k citations

Ranked by citations received across their whole record, among researchers with at least three works on this topic.

What are the most cited papers in Cholangiocarcinoma and Gallbladder Cancer Studies?

The most cited paper in Cholangiocarcinoma and Gallbladder Cancer Studies is "Sorafenib in Advanced Hepatocellular Carcinoma" (Josep Maria Llovet et al., 2008), with 13,116 citations. Next come "Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma" (7,547) and "Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine" (6,826).

Most cited papers
#PaperReleasedCitations
1 Sorafenib in Advanced Hepatocellular Carcinoma Josep Maria Llovet et al. · New England Journal of Medicine Open access 23 Jul 2008 13,116
2 Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma Richard S. Finn et al. · New England Journal of Medicine Open access 13 May 2020 7,547
3 Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine Daniel D. Von Hoff et al. · New England Journal of Medicine Open access 16 Oct 2013 6,826
4 Comprehensive molecular characterization of gastric adenocarcinoma Adam Joel Bass et al. · Nature Open access258 authors 23 Jul 2014 6,680
5 THE TWO HISTOLOGICAL MAIN TYPES OF GASTRIC CARCINOMA: DIFFUSE AND SO‐CALLED INTESTINAL‐TYPE CARCINOMA P Laurén · Acta Pathologica Microbiologica Scandinavica Sep 1965 6,205
All 100 most cited papers, with filters and sorting

Where is Cholangiocarcinoma and Gallbladder Cancer Studies research done?

The largest centres of Cholangiocarcinoma and Gallbladder Cancer Studies research in 2022-now are Beijing (China), Shanghai (China), Seoul (South Korea) and Guangzhou (China). Among places with at least 20 works in it, it is an unusually large share of all research in Khon Kaen, Rozzano and Shizuoka.

Largest cities, 2022-now

  1. 1 BeijingChina 277 works
  2. 2 ShanghaiChina 275 works
  3. 3 SeoulSouth Korea 246 works
  4. 4 GuangzhouChina 244 works
  5. 5 TokyoJapan 186 works
  6. 6 ChengduChina 130 works
  7. 7 HangzhouChina 128 works
  8. 8 NanjingChina 105 works
  9. 9 New YorkUnited States 98 works
  10. 10 WuhanChina 88 works

Where it is the local speciality

  1. Khon KaenTH · 34.7 works18×
  2. RozzanoIT · 23.1 works17×
  3. ShizuokaJP · 29.9 works17×
← less than its size predicts1×more →

Location quotient: how much more of its research is in Cholangiocarcinoma and Gallbladder Cancer Studies than the world average.

See Cholangiocarcinoma and Gallbladder Cancer Studies on the map

Where is the best place to study Cholangiocarcinoma and Gallbladder Cancer Studies?

Among universities, judged by research, Sun Yat-sen University, Fudan University and The Ohio State University score highest, combining citation excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.

0%10%20%30%mean 16.47%fractional works in this field (log) →share of work in the world top 10% →Chinese University o…Fudan UniversitySun Yat-sen UniversityThe Ohio State Unive…
above the meannear itbelow it

One dot per university in the first ten of the table below, at the default weights. The upper left is the interesting corner: small places doing unusually strong work.

Citation excellenceshare of its work in the world top 10%, 2022-now and all time averaged
40%
Specialisationhow much of its work is in this field, counted up to 10× the world share
10%
Sizeits output in this field, on a log scale
30%
Growthoutput growth, counted from -20% to +20%
10%
Internationalshare of its work with a co-author abroad
10%
Each slider sets a weight; the share it gets of the score is beside it.
#UniversityScoreTop 10%SpecialisationWorksGrowth
1Sun Yat-sen UniversityChina 70.915.6%10.7×172 +5.1%
2Fudan UniversityChina 64.720.1%5.8×71 -3.0%
3The Ohio State UniversityUnited States 62.815.4%5.2×49 +18.1%
4Chinese University of Hong KongChina 61.425.5%2.9×16 -31.0%
5Karolinska InstitutetSweden 60.013.1%4.8×21 +58.4%
6Humanitas UniversityItaly 59.618.2%20.5×23 +1.2%
7Sichuan UniversityChina 58.09.7%5.6×98 +34.3%
8Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina 57.514.1%7.1×58 +13.7%
9Harvard UniversityUnited States 57.515.9%2.1×53 -36.5%
10Harbin Medical UniversityChina 56.317.1%11.2×30 +10.5%

Universities only. The score blends citation excellence (40%), size (30%), specialisation (10%), growth (10%), international reach (10%), 2022-now; growth compares 2018-21 with 2022-25 and counts up to +20%, since a jump from a small base is mostly noise.

Every institution in Cholangiocarcinoma and Gallbladder Cancer Studies, country by country

Is Cholangiocarcinoma and Gallbladder Cancer Studies research growing?

Output in 2022-2025 was 7% higher than in 2018-2021, peaking in 2022. The fastest-growing topics are Cholangiocarcinoma and Gallbladder Cancer Studies.

still counting19801990200020102020
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Cholangiocarcinoma and Gallbladder Cancer Studies as a percentage of every work published that year, 0.036% in 2024.

still counting0.020%0.040%0.060%Cholangiocarcinoma and Gallbladder Cancer Studies0.035% in 202519801990200020102020

Fractional works of Cholangiocarcinoma and Gallbladder Cancer Studies over all fractional works that year. How the balance of science has shifted.

How much of it reaches the world top 10%

Year by year.

still counting5%10%15%Cholangiocarcinoma and Gallbladder Cancer Studies9.9% in 2025200020102020

Of each year's works in it, the share that reached the world's 10% most cited for their field and year. A field is the world for its own topics, so there is no other line to hold it against.

Which topics inside it are moving

Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.

Discussion

Ask a question or share a note about Cholangiocarcinoma and Gallbladder Cancer Studies. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.